Morgan Stanley raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $65 from $63 and keeps an Overweight rating on the shares. Q4 was “uneventful” as pipeline progress remains on track and revenues were recently pre-announced, says the analyst, who also notes that management reiterated 2025 sales guidance of $420M-$435M.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIRM:
- Mirum Pharmaceuticals price target raised to $55 from $50 at Baird
- Mirum Pharmaceuticals: Strong Financial Performance and Promising Pipeline Drive Buy Rating
- Promising Growth and Strategic Positioning Make Mirum Pharmaceuticals a Compelling Buy
- Mirum Pharmaceuticals: Strong Financial Performance and Strategic Advancements Drive Buy Rating
- Mirum Pharmaceuticals Reports Strong 2024 Growth